266 related articles for article (PubMed ID: 27107895)
1. KLF17 attenuates estrogen receptor α-mediated signaling by impeding ERα function on chromatin and determines response to endocrine therapy.
Ali A; Ielciu I; Alkreathy HM; Khan AA
Biochim Biophys Acta; 2016 Jul; 1859(7):883-95. PubMed ID: 27107895
[TBL] [Abstract][Full Text] [Related]
2. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
Zhu J; Li X; Su P; Xue M; Zang Y; Ding Y
Oncogene; 2020 Oct; 39(44):6776-6788. PubMed ID: 32973333
[TBL] [Abstract][Full Text] [Related]
4. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells.
Stender JD; Nwachukwu JC; Kastrati I; Kim Y; Strid T; Yakir M; Srinivasan S; Nowak J; Izard T; Rangarajan ES; Carlson KE; Katzenellenbogen JA; Yao XQ; Grant BJ; Leong HS; Lin CY; Frasor J; Nettles KW; Glass CK
Mol Cell; 2017 Mar; 65(6):1122-1135.e5. PubMed ID: 28306507
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
6. Loss of Estrogen-Regulated
Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
[TBL] [Abstract][Full Text] [Related]
7. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
8. miR-190 enhances endocrine therapy sensitivity by regulating SOX9 expression in breast cancer.
Yu Y; Yin W; Yu ZH; Zhou YJ; Chi JR; Ge J; Cao XC
J Exp Clin Cancer Res; 2019 Jan; 38(1):22. PubMed ID: 30658681
[TBL] [Abstract][Full Text] [Related]
9. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
Hao L; Rizzo P; Osipo C; Pannuti A; Wyatt D; Cheung LW; Sonenshein G; Osborne BA; Miele L
Oncogene; 2010 Jan; 29(2):201-13. PubMed ID: 19838210
[TBL] [Abstract][Full Text] [Related]
10. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.
Kondo N; Toyama T; Sugiura H; Fujii Y; Yamashita H
Cancer Res; 2008 Jul; 68(13):5004-8. PubMed ID: 18593897
[TBL] [Abstract][Full Text] [Related]
11. STAT1 facilitates oestrogen receptor α transcription and stimulates breast cancer cell proliferation.
Hou Y; Li X; Li Q; Xu J; Yang H; Xue M; Niu G; Zhuo S; Mu K; Wu G; Li X; Wang H; Zhu J; Zhuang T
J Cell Mol Med; 2018 Dec; 22(12):6077-6086. PubMed ID: 30334368
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
13. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
14. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.
Schultz DJ; Wickramasinghe NS; Ivanova MM; Isaacs SM; Dougherty SM; Imbert-Fernandez Y; Cunningham AR; Chen C; Klinge CM
Mol Cancer Ther; 2010 Mar; 9(3):594-605. PubMed ID: 20197399
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
16. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
Merenbakh-Lamin K; Ben-Baruch N; Yeheskel A; Dvir A; Soussan-Gutman L; Jeselsohn R; Yelensky R; Brown M; Miller VA; Sarid D; Rizel S; Klein B; Rubinek T; Wolf I
Cancer Res; 2013 Dec; 73(23):6856-64. PubMed ID: 24217577
[TBL] [Abstract][Full Text] [Related]
17. Interplay of ERα binding and DNA methylation in the intron-2 determines the expression and estrogen regulation of cystatin A in breast cancer cells.
John Mary DJS; Sikarwar G; Kumar A; Limaye AM
Mol Cell Endocrinol; 2020 Mar; 504():110701. PubMed ID: 31926189
[TBL] [Abstract][Full Text] [Related]
18. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
19. KLF17 empowers TGF-β/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression.
Ali A; Zhang P; Liangfang Y; Wenshe S; Wang H; Lin X; Dai Y; Feng XH; Moses R; Wang D; Li X; Xiao J
Cell Death Dis; 2015 Mar; 6(3):e1681. PubMed ID: 25766320
[TBL] [Abstract][Full Text] [Related]
20. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]